How will Pharmacogenomics look in 2020? Is your company sufficiently prepared? Join FDA regulatory attorney Darshan Kulkarni as he discusses how pharmacogenomics may change in 2020, and whether your clinical trials may be affected.
How might patient centricity progress in 2020, and what does this mean for your company? In this episode, Darshan Kulkarni talks about the different factors affecting clinical trial transparency, and the four branches of patient centricity. We'll...
Pharmacy has undergone a series of changes in 2019. What might this mean for the future of pharmacy? In this episode, Darshan talks about how the rise in cannabis, telepharmacy, and the emergence of the General Data Protection Regulation (GDPR) may...
Pharmacogenomics is the study of how a person's genes affect how he or she responds to medication. Pharmacogenomic testing, however, remains medically necessary in very few cases. How has the increased use of genetic testing led the federal...
Setting up effective, compliant investigational drug pharmacies means reviewing FDA requirements and applicable state boards of pharmacy. Depending on the regulatory body reviewing the pharmacy, different parameters may need to be met. In this...
US Food and Drug Administration (FDA) cracks down on false claims--issuing warning letters to companies for marketing supplements as valid treatment options for Alzheimer’s disease.